The FDA assessed the security and success of atidarsagene autotemcel determined by facts from 37 children who received atidarsagene autotemcel in two single-arm, open-label scientific trials As well as in an expanded entry application.[seven] Little ones who gained cure with atidarsagene autotemcel were being compared to untreated children (natural record).[7] https://sethoqixr.bloggip.com/35817533/new-step-by-step-map-for-lenmeldy